![](https://cardior.de/wp-content/themes/cardior-wp-theme/dist/Components/BlockHeroAnimation/Assets/cardior-therapeutics-non-coding-rna-poster-8b2cc8ab94.jpg)
At the pulse of heart disease
We are pioneers in the discovery and development of non-coding RNA-based therapeutics designed to address the root causes of heart disease.
![A plastic red heart in an indicated rib cage, on a light background](https://cardior.de/wp-content/uploads/resized/2024/02/heart-in-chest-800x0-c-default.jpg)
Mode of Action
The video illustrates how CDR132L operates in cardiac cells to reverse adverse cardiac remodeling and restore normal cellular functions.
CDR132L is currently being evaluated in HF-REVERT Phase 2 Clinical Study in heart failure patients after myocardial infarction.
News
Insight into the history of Cardior, its lead compound CDR132L and the €1B acquisition by Novo Nordisk in an hour-long conversation with Philip Hemme in flot.bio - Europe’s Biotech Podcast.